Stelara, NorLevo move closer to final Japanese approval
This article was originally published in Scrip
Executive Summary
Janssen Pharmaceutical's biologic therapy Stelara (ustekinumab) and Sosei's emergency oral contraceptive (OC) NorLevo (levonorgestrel; SOH-075) have been given positive approval recommendations in Japan, moving them closer to commercialisation in what is likely to become an important market.